Breast Lobular Carcinoma — Trials

Breast Lobular Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

81 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 26
Recruiting: 15
Ph III recruiting: 0
Growth YoY: —
Industry share: 8%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (10)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04570956	Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk	terminated	Phase 2	65	Mayo ClinicOTHER	1	Sep 24, 2026	clinicaltrials
NCT05755269	Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women	terminated	—	19	Mayo ClinicOTHER	1	May 1, 2026	clinicaltrials